|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Britain’s National Health Service (NHS) recently turned 68 years old, and, in spite of its bleak financial situation, the Independent’s Indie 100 shared 11 reasons to celebrate the birthday of the oldest ...
Banking on its Rayaldee treatment, this once-quiet pharmaceutical company has stepped up its investor profile with its first analyst day and a recent move to Nasdaq.
A pending FDA decision, uncertainty about potential markets, and questionable acquisition prices add up to significant risk for Opko shareholders.